Colonoscopy, Functional Constipation, Irritable Bowel Syndrome, Probiotics
Conditions
Brief summary
The purpose of this project is to study the the efficacy and safety of probiotics implantation through infusion during colonoscopy in the treatment of functional constipation and irritable bowel syndrome. The study is a single-center, prospective, randomized, single-blind, controlled, cohort study. The invesitigators plan to enroll 80 patients with functional constipation and 80 patients with irritable bowel syndrome. The invesitigators will randomize the included study subjects. The experimental group receive basic treatment and a single infusion of probiotics through colonoscopy. The control group receive basic treatment and a single injection of normal saline through colonoscopy. The invesitigators will follow up the patients for 8-12 weeks. The primary endpoint is the efficacy of the single colonoscopic probiotics infusion in functional constipation and irritable bowel syndrome patients. The secondary endpoint is the safety of the single colonoscopic probiotics infusion in functional constipation and irritable bowel syndrome patients. Other exploratory objectives include the alterations in clinical indicators, fecal microbiota, and intestinal microbiota metabolites in feces and serum.
Interventions
DRUGLive Combined Bifidobacterium and Lactobacillus
The invesitigators give patients Live Combined Bifidobacterium and Lactobacillus solution infusion during their colonoscopy examination for a single time in the Live Combined Bifidobacterium and Lactobacillus group.
DRUGNormal saline
The invesitigators give patients normal saline as a placebo infusion during their colonoscopy examination for a single time in the control group.
DRUGBasic treatment
The invesitigators give patients general treatment and drug treatment including oral Live Combined Bifidobacterium and Lactobacillus tablets as basic treatment.
Sponsors
First Affiliated Hospital Xi'an Jiaotong University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients undergoing for colonoscopy * Meet Rome IV diagnostic criteria for functional constipation or irritable bowel syndrome * Voluntarily participate in this clinical study and sign the informed consent.
Exclusion criteria
* Use of probiotics or antibiotics within the past 4 weeks * History of intestinal surgery * History of severe liver and kidney disease * History of cardiovascular and cerebrovascular diseases * History of neuropsychiatric diseases * Pregnant women or lactating women * Allergic to any ingredients of the live bacteria tablet
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of effective patients with functional constipation and irritable bowel syndrome patients | 8-12 weeks after start of treatment. | The efficacy of irritable bowel syndrome is evaluated by stool texture and abdominal discomfort related scales including IBS-SSS, BSS score, IBS-QOL,HADS and number of bowel movements per day in 12 weeks after start of treatment. The efficacy of functional constipation is evaluated by weekly defecation frequency, spontaneous complete bowel movement, and scales such as Wexner constipation score, BSS score, and PAC-QOL in 8 weeks after start of treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events related to treatment | 8-12 weeks after start of treatment. | The safety of single colonoscopic probiotics infusion was evaluated by incidence of adverse events related to colonoscopic probiotics infusion during the treatment and 8-12 weeks after the treatment. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Fecal microbiota | 8-12 weeks after start of treatment. | 16S rRNA detection of fecal intestinal flora. |
| Intestinal microbiota metabolites | 8-12 weeks after start of treatment. | Detection of gut microbiota metabolites in blood and feces by HPLC-MS/MS. |
Countries
China
Contacts
Primary ContactYun Feng, M.D.
Backup ContactHongxia Li, M.D.
Outcome results
None listed